A Study to Establish An Integrated Biomarker Panel for COVID-19 Infection Risk and Severity Prediction

Overview

Información sobre este estudio

Aim 1: Determine the basal profile of non-genomic factors in patients at the time of exposure to SARS-CoV-2 and correlate with the three clinical patient outcome categories (A, B, C) as observed through their clinical course. 

Hypothesis: Baseline cytokine (IL-1β, IL-6, IL-4, IL-10, IFN-g and TNF-a) and the immune cellular repertoire (helper/CD4+, cytotoxic/CD8+, T-regulatory cells, natural killer cells) constitute the inherent biologic immunity of an individual and underpins their vulnerability to SARS-CoV-2 infectivity and/or its subsequent sequalae. 

Aim 2: Investigate if mutations or polymorphisms in genes (CXCR6, ACE2 and SLC6A20) linked to SARS-CoV-2 correlates with the three clinical patient outcome categories (A, B, C) as observed through their clinical course.

Hypothesis: ACE2 is a cellular receptor for SARS-CoV-2. The high binding affinity of ACE2 to SARS-CoV-2 is determined by its gene sequence and polymorphisms in the ACE2 gene itself or those that regulate ACE2 function (i.e. SLC6A20) can alter this binding potential and thus the clinical impact of the virus. 

Aim 3:  Develop an integrated model of non-genomic (Aim 1) and genomic (Aim 2) factors for prediction of the three potential clinical courses of an individual upon exposure to SARS-CoV-2.  

Hypothesis:  An integrated model incorporating quantitative analysis of cytokines/immune cells (Aim 1) and gene sequence analysis (Aim 2) will allow a more robust and accurate prediction for one of the three potential clinical courses (A, B, C) after SARS-CoV-2 exposure.  

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Mayo Clinic patients that have had exposure to SARS-CoV2 virus and/or symptoms related to COVID-19 infection and present to Mayo Clinic for testing.
  • Patients that are willing to consent for a blood draw and provide a blood sample.

Exclusion Criteria: 

  • Individuals < 18 years  of age.
  • Patients on active treatment for cancer and/or those on immunosuppressants.
  • Pregnant and breast-feeding women.
  • Patients who have had COVID-19 in the past, confirmed in the medical record.
  • Patients who are unable to give written/verbal consent or are unwilling to participate.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Alicia Algeciras-Schimnich, Ph.D.

Cerrado para la inscripción

Contact information:

Rochelle Fabian M.A.

(507) 538-3259

Fabian.Rochelle@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Pooja Advani, M.B.B.S., M.D.

Cerrado para la inscripción

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publicaciones

Publications are currently not available